Nexelis, a Q2 Solutions Company

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offer of services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis, a Q2 Solutions Company, is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 350 new molecular entities, including blockbuster vaccines and...

Novel biomarker assay development,immunochemistry assays,protein services,molecular biology,functional viral and bacterial assays,cellular immunology,bioanalytical services,pharmacokinetic testing,immunogenicity testing,fit-for-purpose biomarkers,preclinical services,animal study design,in vivo study approaches,study readouts,immunogenicity,immuno-oncology,in vitro models,ligand binding assays,and lc/ms hrlc/ms

Nexelis, a q2 solutions company operates in the Pharmaceutical manufacturing industry.

Nexelis, a q2 solutions company's revenue is 11m - 100m

Nexelis, a q2 solutions company has 201 - 500 employees.